IntelGenx Corp.
OTC Bulletin Board : IGXT

IntelGenx Corp.

October 31, 2007 08:31 ET

IntelGenx Technologies Corp. Will Present Recent Achievements and Market Opportunities at Rodman & Renshaw's 9th Annual Healthcare Conference, November 7, 2007

SAINT LAURENT, QUEBEC--(Marketwire - Oct. 31, 2007) - IntelGenx Technologies Corporation (OTCBB:IGXT) ("IntelGenx" or the "Company"), a drug delivery company creating novel oral-delivery technologies for generic pharmaceutical markets, will present the Company's recent achievements and expanding market opportunities at Rodman & Renshaw's 9th Annual Healthcare Conference on Wednesday, November 7, 2007 at 1:20 EST. The conference is being held November 5-7 at the New York Palace Hotel.

Dr. Horst Zerbe, President and CEO, will discuss the advantages of IntelGenx's proprietary oral-delivery technologies in today's changing pharmaceutical industry. The Company currently has a pipeline of 11 products and partnerships with four pharmaceutical companies, and reported a revenue increase of more than 124% for the six months ended June 30, 2007, compared to the same period in 2006.

The Conference - attended by investors, venture capitalists, company executives, scientists and other industry leaders - will include presentations by over 350 companies, as well as experts from the medical, scientific and investment communities.

Dr. Zerbe said, "We believe this sophisticated audience from the investment community will appreciate the substantial near-term growth and low-risk opportunity our company offers. Our novel technology makes us highly competitive on the generic market. The number of projects in our portfolio has increased rapidly. We currently have almost $1 million in cash and our burn rate is very low compared to other development companies of our size. Our technology is proven, our development risks are very low, and we expect our first product to be on the market in the first quarter of 2008."

About Intelgenx Corp.

IntelGenx Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The company's research and development pipeline includes products for the treatment of osteoarthritis, pain management, hypertension, and smoking cessation.

Contact Information

  • IntelGenx Corp.
    Dr. Horst G. Zerbe
    President and CEO
    (514) 331-7440 (ext. 201)
    (514) 331-0436 (FAX)
    Email: horst@IntelGenx.com
    Website: www.intelgenx.com
    or
    Investor Relations:
    Consulting for Strategic Growth 1
    Stanley Wunderlich, CEO
    1-800-625-2236
    (212) 337-8089 (FAX)
    Email: info@cfsg1.com
    or
    Media Relations:
    Consulting for Strategic Growth 1
    Daniel Stepanek
    (212) 896-1202
    (212) 697-0910 (FAX)
    Email: dstepanek@cfsg1.com
    Website: www.cfsg1.com